APPLICATION OF DATA VISUALIZATION TOOL- TREATMENT PATTERNS OF MEDICARE PATIENTS WITH ANKYLOSING SPONDYLITIS WHO INITIATED TUMOR NECROSIS FACTOR THERAPY
Author(s)
Baser O1, Wang L2, Xie L3, Yuce H41STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 3STATinMED Research, Ann Arbor, MI, USA, 4New York City College of Technology-CUNY / STATinMED Research, New York, NY, USA
OBJECTIVES: In recent years, methodologies used in outcomes research have advanced. In a field where many disciplines, such as clinicians, epidemiologists, economists and statisticians interact frequently, a tool to communicate information clearly and effectively through graphical means has become a necessity.To present treatment patterns among patients diagnosed with ankylosing spondylitis (AS) using data visualization techniques. METHODS: Using 100% national Medicare data with Part D information, we selected patients over the age of 65 with at least one AS diagnosis. We identified patients who initiated therapy with tumor necrosis factor (TNF) and non-TNF agents. For 2 years after the initiation, we examined switching to another TNF, a non-TNF, and discontinuation treatment patterns. Using a processing language, we created a data visualization tool to demonstrate changes in treatment patterns after the first and second switches. RESULTS: A total of 1,159 AS patients (1,159) initiated therapy with TNF. 5.69% of these patients switched to another TNF, 2.67% switched to a non-TNF, 55.91% discontinued therapy and 35.72% continued their initial therapy. Among patients who switched to another TNF, 53.03% remained on the switched therapy, 28.79% discontinued therapy, 15.15% switched to another TNF, and 3.03% switched to a non-TNF. A total of 532 AS patients initiated therapy with a non-TNF. 1.50% of these patients switched to a TNF, 0.94% switched to a non-TNF, 93.61% discontinued their therapy and 3.95% continued their initial therapy. CONCLUSIONS: Treatment patterns can be difficult to present, especially when analyzing several years of data and various drug switches. Data visualization tools can help present these complicated flows effectively to researchers.
Conference/Value in Health Info
2012-06, ISPOR 2012, Washington, D.C., USA
Value in Health, Vol. 15, No. 4 (June 2012)
Code
PSY8
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Systemic Disorders/Conditions